IL17A and type 2 diabetes mellitus: PGZ therapy in animal models, patients with T2DM, and obese subjects has shown beneficial effects on diverse inflammatory parameters such as reduced infiltration of macrophages, neutrophils, and dendritic cells as well as suppressed expression of Tumor necrosis factor-alpha (TNF-α), Interleukin-6 (IL-6), and Interleukin-17 (IL-17) [19,20].